Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple MyelomaInterventions:   Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine;   Biological: sargramostim;   Biological: aldesleukin;   Other: laboratory biomarker analysisSponsors:   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)Active, not recruiting - verified May 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials